Lipids in erythrocytes and plasma of children and adults with terminal renal insufficiency were determined and compared with those of normal controls. The erythrocyte phospholipids in uremic patients were altered in phosphatidylethanolamine (absolutely and relatively elevated) and in lecithin (relatively diminished). Sphingomyelin, phosphatidylserine, total erythrocyte phospholipid content and cholesterol were within the normal range. The detailed analysis of the distribution of plasma phospholipids showed an increase in all phospholipids except phosphatidylserine. The unesterified plasma cholesterol was also found to be elevated. The fatty acid distribution in the individual erythrocyte phospholipids showed the following variations in comparison with controls: one main fatty acid was significantly decreased in sphingomyelin and in lecithin and slightly decreased in phosphatidylethanolamine. It could be shown that the lipid alterations in uremic erythrocytes were quite different from those in plasma. There were no typical signs for an increased lipid peroxidation in the erythrocytes of patients with renal insufficiency.

Keywords:
Erythrocyte lipids, Plasma lipids, Phospholipid fatty acids, Terminal renal insufficiency
This content is only available via PDF.
© 1980 S. Karger AG, Basel
1980
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.